Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
Bernstein analyst Miki Sogi maintained a Buy rating on Chugai Pharmaceutical Co (CHGCF – Research Report) yesterday and set a price target of ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
AstraZeneca and Daiichi Sankyo ’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer patients with very low levels of HER2 protein.
New approval brings the medicine to an earlier treatment setting and a broader patient population.
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
The comments mark the latest in a number of trade-related threats unleashed by Trump in recent days. Trump said he plans to ...
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback